Sign up Australia
Proactive Investors - Run By Investors For Investors

Bod Australia’s shares rise as it prepares to launch cannabis-based cosmetics

Planning to commercialise and distribute the products to consumers by 2018.
cannabis plant
Partnership with Swiss herbal extracts company

Bod Australia Ltd (ASX:BDA) has commenced exploratory formulation work on a new range of cannabis-based cosmetic products via its partnership with Swiss herbal extracts company Linnea SA.

Bod’s share prices has increased 70% in the past one week and is trading at $0.17 intra-day.

Pursuant to the agreement, Linnea will also assist Bod in developing cannabis-based topical treatments for inflammation and sensitive skin, including serums, foam-based creams and balms.

A key value-driver for the new cosmetic range will be the use of Linnea’s unique NioSkin™ ingredient as an active ingredient and transporter of the cannabis.

NioSkin provides superior therapeutic outcomes than standard cannabis cosmetics by efficiently enhancing skin penetration of the cannabis-based extracts.

Bod is currently conducting research and development for its cannabis-based skincare products and is planning to commercialise and distribute the products to consumers by 2018.

The products will be developed and manufactured at facilities in Italy, and exported to numerous major markets beyond Australia, including Asia and the Americas.

Discussions are underway with third-parties for white labelling and wholesale distribution.

The global skincare market is expected to reach $233.7 billion by 2022.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full BDA profile View Profile

Bod Australia Ltd Timeline

Related Articles

researcher filling a vial
July 16 2018
The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
consumer health segment overview
The company sells clinically validated anti-ageing products for hair, skin and body.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use